TD Cowen upgraded shares of Incyte to strong-buy rating and adjusted price targets on August 25, 2026.
1 report, 1 independent
Updated Aug 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen upgraded shares of Incyte to strong-buy rating and adjusted price targets on August 25, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
- TD Cowen analysts are scrutinizing the business strategies of major financial institutions, including U.S. Bancorp and Wells Fargo, while Morgan Stanley also contributes to the inquiry.
- Multiple financial firms, including Morgan Stanley and TD Cowen, updated price targets and ratings for various institutions on October 31, 2026.
-
Incyte
American pharmaceutical company
Nothing else this week.
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
Related events
- Truist Financial, Leerink partners, and Morgan Stanley have raised price targets and weighed in on Incyte stock.
- TD Cowen reiterated a buy rating on MBX Biosciences shares, and Citigroup restated an outperform rating on the company.
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- Truist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.
- TD Cowen restated a 'buy' rating on Affiliated Managers Group (AMG) on June 6, 2026.